Associate Director
CSL Behring
Ankur Sharma obtained his B. Pharm from University of Rajasthan, Jaipur, India and his MS in Pharmacology from Rajiv Gandhi Technical University, Bhopal, India. After his MS he worked as a Research Associate in pre-clinical pharmacology R&D department of Piramal Life Sciences in India. Ankur Sharma has received his Ph.D. in Pharmaceutical Sciences from The University of Oklahoma. He was an ORISE fellow in the US FDA. Later Ankur joined Merck as a Sr. scientist in the Quantitative Pharmacology and Pharmacometrics group. His responsibilities included projection of human dose from nonclinical data to support FIH study design, development of population PK/PKPD models for anticancer and inhaled drugs, and establishment of a PBPK platform for studying the PK of drugs administered ocularly. In his role as a Associate Director, Clinical Pharmacology and Pharmacometrics, Ankur is responsible for providing PMX support across all stages of development. His work will include translation of nonclinical data to inform FIH dose selection and development of population PKPD and ER models to inform dose selection for Ph II and III trials.
His significant research contributions include utilizing quantitative approaches like PBPK and PK/PD modeling for prediction of drug levels in tumors with a possibility of human scale-up for FIH dose selection in cancer patients, determining mechanistic strategies to overcome tumor-resistance in ovarian cancer, BA method development for analysis of anti-cancer drugs in human plasma, utilizing PBPK approaches for ocular translation from animal data to predict human ocular PK/PD, and developing prodrugs for NSAIDs for improved efficacy and safety.
He has published his work in eminent journals like The AAPS Journal, PLOS One, Journal of Pharmaceutical Technology and Drug Development, Bioorganic Med Chem Letters and Chem Pharm Bulletin and have presented posters in conferences like AAPS and ACOP. He is also a reviewer for many journals.
.png)